Arthritis - septic
Also known as: Arthritic, Arthritis, Infarction, Stroke
Methodology & AI Transparency ⓘ
Arthritis - septic Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry M00.80: Arthritis - septic is managed within Arthritis & Joints (aka Arthritic).
- 3 Typical cash cost range: Clinicians assessing Arthritis - septic focus on monosodium urate or in Arthritis - septic (M00.80: calcium pyrophosphate crystal) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Arthritis - septic: Weight-Bearing Joint Radiograph [Arthritis - septic M00.80] (Preserved joint-space width (M00.80)) and Serum Uric Acid in Arthritis - septic (M00.80: (Gout Target)).
Ask our AI Specialists anything about Arthritis - septic
What Is Arthritis - septic?
Recognized across U.S. clinical coding as M00.80 (Arthritis & Joints), Arthritis - septic (also termed Arthritic or Arthritis) is evaluated via synovial fluid crystal/cell in Arthritis - septic (M00.80: analysis when effused) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Arthritis - septic (ICD-10 M00.80) is driven by monosodium urate or in Arthritis - septic (M00.80: calcium pyrophosphate crystal); specialists in Osteoarthritis, Gout & Joint Pain monitor Serum Uric Acid in Arthritis - septic (M00.80: (Gout Target)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Arthritis - septic (M00.80): brief morning joint in Arthritis - septic (M00.80: stiffness)
- • Secondary Arthritis - septic clinical sign: sudden, intensely painful, in Arthritis - septic (M00.80: red swollen big-toe)
- • Symptom flares in Arthritis - septic correlating with Weight-Bearing Joint Radiograph [Arthritis - septic M00.80] deviation outside Preserved joint-space width (M00.80)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Arthritis - septic (M00.80: analysis when effused) evaluation (M00.80)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Arthritis - septic Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M00.80 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Arthritis - septic M00.80] | Preserved joint-space width (M00.80) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Arthritis - septic (M00.80: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M00.80) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Arthritis - septic (M00.80: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M00.80) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Arthritis - septic
Treatment selection for Arthritis - septic depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Arthritis - septic)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of upadacitinib in autoimmune joint pain (rheumatoid arthritis):: What a 2,630-Participant Study Found In the phase III clinical programme for RA, patients receiving upadacitinib had an increased risk of herpes zoster and CPK elevation versus adalimumab. Annals of the rheumatic diseases • 2021-03-15 • Phase III Randomized Trial | N = 2,630 | 96/100 | PMID 33115760 ↗ |
| New Insights on Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in: What a 1,120-Participant Study Found Guselkumab 100 mg Q4W and Q8W were well tolerated in patients with PsA, with no new safety concerns through 1Y of the phase III DISCOVER trials. The Journal of rheumatology • 2021-12-15 • Phase III Randomized Trial | N = 1,120 | 96/100 | PMID 33934076 ↗ |
| New Insights on Benefits and safety of filgotinib in patients with moderately active autoimmune: What a 1,755-Participant Study Found In this subpopulation with moderately active RA, the real-world benefits and safety of filgotinib were similar to those in the overall FINCH 1 population (patients with active moderate to severe RA). Rheumatology (Oxford, England) • 2025-04-01 • Phase III Randomized Trial | N = 1,755 | 96/100 | PMID 39331638 ↗ |
| New Insights on Exercise Type and Duration on Pain, Function, and Quality of Life in Patients: What a 3,808-Participant Study Found J Orthop Sports Phys Ther 2026;56(11):724-734. The Journal of orthopaedic and sports physical therapy • 2026-11-15 • Meta-Analysis | N = 3,808 | 94/100 | PMID 42966901 ↗ |
| New Insights on Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in: What a 555-Participant Study Found Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2021-01-15 • Phase III Randomized Trial | N = 555 | 93/100 | PMID 32770640 ↗ |
Arthritis - septic Patient Community & “People Like Me” Threads
Filter Arthritis - septic community threads and patient logs by age, biological sex, dosage, and treatment duration.